Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Boston Omaha Approves $30 Million Stock Repurchase Program

Boston Omaha Corporation filed a current report on Form 8-K on September 11, 2026, disclosing that its Board of Directors approved a new $30 million Class A common stock repurchase program effective November 1, 2026.

Vinay Lochav | 11 September 2026

Hudson Pacific Properties Extends $1.1B Film Portfolio Loan

Hudson Pacific Properties, Inc. (NYSE:HPP) filed an 8-K on September 11, 2026, disclosing that subsidiaries and affiliates of its Operating Partnership entered into an Extension and Loan Modification Agreement on September 9, 2026, extending the maturity of a $1.1 billion CMBS mortgage financing secured …

Aakashdeep | 11 September 2026

Silexion Therapeutics (NASDAQ: SLXN) Rises 21% Ahead of September Industry Events

Silexion Therapeutics Corp. (NASDAQ: SLXN) shares closed up 21% at $0.42 after announcing its attendance at upcoming September 2026 industry events, whereLeadershipwill highlight oncology progress and the pan-KRAS RNAi candidate SIL204 in pancreatic cancer.

Nitish Kishor | 11 September 2026

Tenon Medical (NASDAQ: TNON) Surges 117% on Full Convertible Notes Repayment

Tenon Medical, Inc. (NASDAQ: TNON) shares closed up 117% at $5.30 on news that the company fully repaid about $5.16 million of senior convertible notes ahead of maturity.

Nitish Kishor | 11 September 2026

AEON Biopharma (NYSE: AEON) Rises 26% on ABP-450 Comparability Data

AEON Biopharma, Inc. (NYSE: AEON) shares closed up 26% at $0.29 after the company reported pilot forced-degradation data showing ABP-450 had comparable thermal potency-loss and oxidative-stress patterns to BOTOX.

Nitish Kishor | 11 September 2026

CDT Equity (NASDAQ: CDT) Falls 43% Following Sarborg Update

CDT Equity (NASDAQ: CDT) shares fell 43% to $0.34 following an update noting minority-owned Sarborg's use of patented Signature Intelligence and quantum models in neuropsychiatric drug discovery, covering depression, bipolar disorder, anxiety, and schizophrenia.

Nitish Kishor | 11 September 2026

Indaptus Therapeutics (NASDAQ: INDP) Rises 23% on Capital Raise and Strategic Review

Indaptus Therapeutics, Inc. (NASDAQ: INDP) shares closed up 23% at $2.56 following its second-quarter 2026 update, which emphasized enhanced capital reserves via a $12.0 million private placement.

Nitish Kishor | 11 September 2026

NeuroSense Therapeutics (NASDAQ: NRSN) Falls 17% on 1-for-20 Reverse Stock Split

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) shares fell 17% to $0.33 after the company announced it will implement a 1-for-20 reverse share split, with post-split Nasdaq trading expected to begin September 14, 2026.

Nitish Kishor | 11 September 2026

Wall Street Futures Rise on August CPI as Fed Rate Decision Hangs in the Balance

Stock futures were higher Friday as oil prices declined and traders digested August'sConsumer Price Indexreport. Futures linked to theDow Jones Industrial Averagewere up 470 points, or 0.9%. S&P 500 futures climbed 0.9%, while Nasdaq-100 futures advanced 1%. A gain for the major averages would …

Nitish Kishor | 11 September 2026

US Consumer Prices Rise 3.4% in August as Gasoline Drives Monthly Gain

Prices for a wide range of goods and services continued climbing in August, with the Consumer Price Index rising a seasonally adjusted 0.4% for the month, putting the 12-month increase at 3.4%. Both figures matched July's readings and came in line with forecasts. The …

Nitish Kishor | 11 September 2026
Support

Hi! How can we help you today?

Loading…